HRS-1167

N/A

Report date: 2024/08/05 17:22:14
NME

Base Information

Drug NameHRS-1167
Drug Alias NameHRS-1167M9466M-9466
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSpain +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEmd Serono Research & Development Institute IncFudan UniversityMerck KGaA, Darmstadt, Germany +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A